Cohance Lifesciences Limited — Important, 07-12-2024: General Updates

Suven Pharmaceuticals Limited has acquired a controlling 56% stake in NJ Bio, Inc. for an investment of approximately $64.4 million, enhancing its position as a technology-driven CDMO specializing in advanced drug formulations. This strategic acquisition is poised to strengthen Suven's R&D and manufacturing capabilities in the USA, a critical market for antibody-drug conjugates (ADCs). NJ Bio adds significant expertise in ADC technologies, backed by a strong client base and impressive growth, projecting revenues of around $32 million for CY24, highlighting a robust CAGR of over 70% since CY21. The US-based firm, with its state-of-the-art facility, will complement Suven's offerings, presenting high cross-selling potential and expanding total addressable market opportunities from $200 million to $1.4 billion in the ADC/CDMO sector. Anticipating the transaction's closing before December 2024, the move aligns with Suven's vision to be a global leader in this fast-evolving field. Investors should watch closely as Suven integrates NJ Bio's capabilities, which may drive accelerated growth.